Patient Preference Evidence Integration Lead
Pfizer
Brett Hauber, PhD, is Patient Preference Evidence Integration Lead in the Chief Medical Office at Pfizer. He is also Affiliate Associate Professor in the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington School of Pharmacy. He received his PhD from the University of Delaware and has over 25 years of experience in health preference research.
Brett currently serves as Pfizer’s representative on the PhRMA Patient Focused Drug Development Working Group and is Deputy Topic Lead for the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E22 Expert Working Group developing consensus guidelines on General Considerations for Patient Preference Studies. He is also the industry lead for the Innovative Health Initiative (IHI) public-private partnership project for Patient-Centred Clinical-Study Endpoints Derived Using Digital Health Technologies.
Brett was a member of the IMI PREFER project and led the Points to Consider for Methods Selection section of the framework that was successfully submitted to EMA for a qualification opinion. He was the Principal Investigator on the Catalogue of Patient Preference Methods developed by the Medical Device Innovation Consortium. He has been a member of multiple ISPOR Task Forces on preference elicitation and Chaired the ISPOR Task Force for Good Research Practices for the Statistical Analysis of Discrete-Choice Experiments.
Prior to joining Pfizer, Brett was a Senior Fellow at RTI International and Vice President of Health Preference Assessment in RTI Health Solutions.
Wednesday, October 8, 2025
4:30 PM - 5:30 PM EST